|
|
Article: Titan Initiates Controlled Phase II Clinical Study of DITPA in the Treatment of Elevated Cholesterol Levels.
- Article from:
- PR Newswire
- Article date:
- March 7, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO, March 7 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals Inc., announced today the initiation of a Phase II study of DITPA (3,5-diiodothyropropionic acid) in the treatment of elevated cholesterol levels. This study will evaluate the cholesterol-lowering properties of DITPA administered in combination with standard statin therapy, in individuals who are unable to achieve targeted cholesterol level reductions with statin therapy alone. This investigator sponsored study is being conducted at The Johns Hopkins Medical Institutions in Baltimore, Maryland.
Recent data have indicated that further lowering of target LDL cholesterol level guidelines may ...